Key life sciences industry representatives have written to the Secretary of State for Health and Social Care to emphasise the need to work with the European Union (EU).
The industry represented by the signatories has an annual turnover of £64 billion, and supports 233,000 jobs, making it a crucial feature of the UK’s post-Brexit economy.
The letter acknowledges the Government’s policy to enact Brexit and depart the single market and EU customs union. It also refers to the previous steps in the Brexit process which reassured the industry of continued cooperation with the EU:
“All the organisations who have signed this letter have welcomed the commitment in the revised Political Declaration on the Future Relationship to explore the possibility of cooperation of United Kingdom authorities with Union agencies such as the European Medicines Agency (EMA) and your comments at the BIA conference which reiterated that position.”
The letter is signed by Steve Bates, Chief Executive, UK BioIndustry Association (BIA), Leslie Galloway, Chairman, Ethical Medicines Industry Group (EMIG); John Smith, Chief Executive, Proprietary Association of Great Britain (PAGB); Warwick Smith, Director General, British Generic Manufacturers Association (BGMA); Mike Thompson, Chief Executive, Association of the British Pharmaceutical Industry (ABPI); and Doris-Ann Williams MBE, Chief Executive, British In Vitro Diagnostic Association (BIVDA).
Read the full letter here.